10-YEAR DYNAMIC OF FREQUENCY, USED DOSES AND ORIGINAL AND GENERIC FORMS OF MAIN DRUG GROUPS IN CORONARY HEART DISEASE REGISTRY

Abstract

Abstract Objective: To assess dynamics of reception frequency, used doses and use of original and generic forms of antiplatelet drugs, statins, beta-blockers, ACE-inhibitors/ARBs in stable coronary heart disease (CHD) patients in 2004–2014 within the CHD registry. Design and method: Patients with angiographically confirmed in 2004–2007 CHD, who came for a follow-up visit in 2010 (n = 303) and in 2014 (n = 125) were included. Results: Statins were taken by 7.6% of patients prior to hospitalization and by 86.5% of patients at discharge, antiplatelet drugs by 68% and 96%, beta-blockers by 24,8% and 94%, and ACE-inhibitors by 19% and 83% of patients, respectively (p < 0.001). Statins were taken by 67% and 70% of patients 4 and 7 years after discharge, respectively, antiplatelet drugs by 80% and 90%, beta-blockers by 80% and 75%, ACE-inhibitors by 66% and 65% of patients, respectively. The main 4 groups of drugs for secondary prevention of CHD were taken by 15% of patients prior to hospitalization, by 69% of patients at discharge (p < 0.001), by 41% 4 years, and by 35% 7 years after discharge (p < 0.01). From 2004 to 2014 all groups of drugs with an exception of antiplatelets were used in low and medium doses with an increase in the use of generic forms, especially for statins (76%). Conclusions: Frequency of assignment of beta-blockers, ACE-inhibitors/ARBs and statins in patients with stable CHD was low prior to hospitalization, increased during their hospital stay and decreased 4 and 7 years after discharge. Throughout these 10 years all drugs were used in medium and low doses, with an increase in the use of generic forms.